InflaRx (IFRX) Assets Average (2017 - 2026)
InflaRx's (IFRX) quarterly Assets Average came in at $125.6 million in Q2 2026, up 43.86% year-over-year from $87.3 million in Q2 2025, and up 106.77% quarter-over-quarter from $60.8 million in Q1 2026.
Analysis
InflaRx (IFRX) Assets Average (2017 - 2026) Analysis & Trends
InflaRx has disclosed Assets Average across 10 years of filings, most recently posting $125.6 million for Q2 2026.
- In Q2 2026, Assets Average rose 43.86% year-over-year to $125.6 million; the TTM figure through Jun 2026 stood at $125.6 million (up 43.86% YoY), while the FY2025 annual figure was $71.8 million, down 31.8% from the prior year.
- Assets Average came in at $125.6 million for Q2 2026 at InflaRx, up from $60.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $142.9 million in Q3 2023 to a low of $60.8 million in Q1 2026.
- Average Assets Average over 5 years is $105.7 million, with a median of $108.3 million recorded in 2022.
- Year-over-year, Assets Average plunged 37.57% in 2024 and jumped 43.86% in 2026.
- Over 5 years, Assets Average stood at $108.3 million in 2022, then increased by 24.84% to $135.1 million in 2023, then slumped by 37.57% to $84.4 million in 2024, then dropped by 16.77% to $70.2 million in 2025, then soared by 78.89% to $125.6 million in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $125.6 million in Q2 2026, $60.8 million in Q1 2026, and $70.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.51 Bn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | 125.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 125.62 Mn |
| Mar 31, 2026 | 60.76 Mn |
| Dec 31, 2025 | 70.22 Mn |
| Sep 30, 2025 | 79.65 Mn |
| Jun 30, 2025 | 87.32 Mn |
| Mar 31, 2025 | 86.37 Mn |
| Dec 31, 2024 | 84.37 Mn |
| Sep 30, 2024 | 93.85 Mn |
| Jun 30, 2024 | 108.27 Mn |
| Mar 31, 2024 | 122.84 Mn |
| Dec 31, 2023 | 135.15 Mn |
| Sep 30, 2023 | 142.87 Mn |
| Jun 30, 2023 | 118.71 Mn |
| Mar 31, 2023 | 98.56 Mn |
| Dec 31, 2022 | 108.26 Mn |
| Sep 30, 2022 | 117.18 Mn |
| Jun 30, 2022 | 125.74 Mn |
| Mar 31, 2022 | 136.16 Mn |
| Dec 31, 2021 | 147.86 Mn |
| Sep 30, 2021 | 157.59 Mn |